179 related articles for article (PubMed ID: 25326567)
1. The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Talbot B; Wright D; Basnayake K
BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25326567
[TBL] [Abstract][Full Text] [Related]
2. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
3. Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Susantitaphong P; Tiranathanagul K; Eiam-Ong S
Artif Organs; 2012 Sep; 36(9):845-6. PubMed ID: 22497276
[No Abstract] [Full Text] [Related]
4. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
Gharwan H; Truica CI
Med Oncol; 2012 Jun; 29(2):1197-201. PubMed ID: 21479696
[TBL] [Abstract][Full Text] [Related]
5. [Update in multiple myeloma: international criteria for treatment response and renal complications].
Decaux O; Karras A
Rev Med Interne; 2009 Dec; 30(12):1080-3. PubMed ID: 19833418
[No Abstract] [Full Text] [Related]
6. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Jimenez-Zepeda VH; Vajpeyi R; John R; Trudel S
Int J Hematol; 2012 Jul; 96(1):125-31. PubMed ID: 22573235
[TBL] [Abstract][Full Text] [Related]
7. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
8. Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.
Wu CK; Yang AH; Lai HC; Lin BS
BMC Nephrol; 2017 May; 18(1):170. PubMed ID: 28545410
[TBL] [Abstract][Full Text] [Related]
9. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
10. Renal improvement in myeloma with plasma exchange.
Hutchison C; Bridoux F; Fermand JP
N Engl J Med; 2011 Sep; 365(11):1061; author reply 1062. PubMed ID: 21916654
[No Abstract] [Full Text] [Related]
11. Renal improvement in myeloma with bortezomib plus plasma exchange.
Burnette BL; Leung N; Rajkumar SV
N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
[No Abstract] [Full Text] [Related]
12. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
13. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
[TBL] [Abstract][Full Text] [Related]
14. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
17. A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio.
Zhang S; Ni H; Xu Q; Cai X; Li H; Wei Z; Cao J
Ren Fail; 2022 Dec; 44(1):103-105. PubMed ID: 35156899
[No Abstract] [Full Text] [Related]
18. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
19. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
20. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
